Death rates and leading causes of death according to the development of post-transplantation pp65-antigenemia
| . | All patients . | Patients with pp65-antigenemia . | Patients without pp65-antigenemia . | P . |
|---|---|---|---|---|
| Overall death rate* | 113/266 (42) | 21/77 (27) | 92/189 (49) | < .002 |
| Relapse-related* | 67/266 (25) | 6/77 (8) | 61/189 (32) | < .0001 |
| Non–relapse-related* | 46/266 (17) | 15/77 (19) | 31/189 (16) | NS |
| Until day 100† | 7/46 (15) | 2/15 (13) | 5/31 (16) | NS |
| After day 100† | 39/46 (85) | 13/15 (87) | 26/31 (84) | NS |
| Acute GVHD with or without fatal infections† | 14/46 (30) | 4/15 (27) | 10/31 (32) | NS |
| Chronic GVHD with or without fatal infections† | 11/46 (24) | 4/15 (27) | 7/31 (23) | NS |
| Fatal infections without GVHD† | 7/46 (15) | 2/15 (13) | 5/31 (16) | NS |
| Hepatic VOD† | 3/46 (7) | 1/15 (7) | 2/31 (6) | NS |
| Bronchiolitis, COLD† | 4/46 (9) | 2/15 (13) | 2/31 (6) | NS |
| Cardiomyopathy, myocardial infarction† | 4/46 (9) | 1/15 (7) | 3/31 (10) | NS |
| PML† | 2/46 (4) | 1/15 (7) | 1/31 (3) | NS |
| HIV infection† | 1/46 (2) | — | 1/31 (3) | — |
| . | All patients . | Patients with pp65-antigenemia . | Patients without pp65-antigenemia . | P . |
|---|---|---|---|---|
| Overall death rate* | 113/266 (42) | 21/77 (27) | 92/189 (49) | < .002 |
| Relapse-related* | 67/266 (25) | 6/77 (8) | 61/189 (32) | < .0001 |
| Non–relapse-related* | 46/266 (17) | 15/77 (19) | 31/189 (16) | NS |
| Until day 100† | 7/46 (15) | 2/15 (13) | 5/31 (16) | NS |
| After day 100† | 39/46 (85) | 13/15 (87) | 26/31 (84) | NS |
| Acute GVHD with or without fatal infections† | 14/46 (30) | 4/15 (27) | 10/31 (32) | NS |
| Chronic GVHD with or without fatal infections† | 11/46 (24) | 4/15 (27) | 7/31 (23) | NS |
| Fatal infections without GVHD† | 7/46 (15) | 2/15 (13) | 5/31 (16) | NS |
| Hepatic VOD† | 3/46 (7) | 1/15 (7) | 2/31 (6) | NS |
| Bronchiolitis, COLD† | 4/46 (9) | 2/15 (13) | 2/31 (6) | NS |
| Cardiomyopathy, myocardial infarction† | 4/46 (9) | 1/15 (7) | 3/31 (10) | NS |
| PML† | 2/46 (4) | 1/15 (7) | 1/31 (3) | NS |
| HIV infection† | 1/46 (2) | — | 1/31 (3) | — |
VOD indicates veno-occlusive disease; COLD, chronic obstructive lung disease; PML, progressive multifocal leukencephalopathy; HIV, human immunodeficiency virus (sexually transmitted after transplantation); NS, not significant; and —, not applicable.
Proportion of patients (%).
Proportion of deceased patients (%).